ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Novel Coronavirus (COVID-19) Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: November 2024
|
Report Code: QYRE-Auto-29K5790
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Novel Coronavirus COVID 19 Vaccine Market Size Status and Forecast 2022 2028
BUY CHAPTERS

Novel Coronavirus (COVID-19) Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-29K5790
Report
November 2024
Pages:149
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart Inc.
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd
Generex
Novavax Inc
Sanofi Pasteur
Baylor
IBio Inc.
Moderna, Inc
CureVac
ImmunoPrecise

Novel Coronavirus (COVID-19) Vaccine - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Novel Coronavirus (COVID-19) Vaccine - Market

Novel Coronavirus (COVID-19) Vaccine - Market

The global market for Novel Coronavirus (COVID-19) Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Novel Coronavirus (COVID-19) Vaccine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Novel Coronavirus (COVID-19) Vaccine by region & country, by Type, and by Application.
The Novel Coronavirus (COVID-19) Vaccine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Coronavirus (COVID-19) Vaccine.
Market Segmentation

Scope of Novel Coronavirus (COVID-19) Vaccine - Market Report

Report Metric Details
Report Name Novel Coronavirus (COVID-19) Vaccine - Market
CAGR 5%
Segment by Type:
  • DNA
  • RNA
  • Others
Segment by Application
  • Mild Symptom Patient
  • Critically Ill Patient
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., GeoVax, Inc., Bravovax, Janssen Pharmaceutical Companies, Altimmune, Vaxart, CanSino Biologics, ExpreS2ion Biotechnologies ApS, Clover Biopharmaceuticals, GSK, Vaxil Bio Ltd., Generex, Novavax, Inc., Sanofi Pasteur, Baylor, iBio, Inc., Moderna, Inc., Curevac, ImmunoPrecise
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Novel Coronavirus (COVID-19) Vaccine manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Novel Coronavirus (COVID-19) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Novel Coronavirus (COVID-19) Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Novel Coronavirus (COVID-19) Vaccine - Market report?

Ans: The main players in the Novel Coronavirus (COVID-19) Vaccine - Market are Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., GeoVax, Inc., Bravovax, Janssen Pharmaceutical Companies, Altimmune, Vaxart, CanSino Biologics, ExpreS2ion Biotechnologies ApS, Clover Biopharmaceuticals, GSK, Vaxil Bio Ltd., Generex, Novavax, Inc., Sanofi Pasteur, Baylor, iBio, Inc., Moderna, Inc., Curevac, ImmunoPrecise

What are the Application segmentation covered in the Novel Coronavirus (COVID-19) Vaccine - Market report?

Ans: The Applications covered in the Novel Coronavirus (COVID-19) Vaccine - Market report are Mild Symptom Patient, Critically Ill Patient

What are the Type segmentation covered in the Novel Coronavirus (COVID-19) Vaccine - Market report?

Ans: The Types covered in the Novel Coronavirus (COVID-19) Vaccine - Market report are DNA, RNA, Others

Recommended Reports

COVID-19 Vaccines & Therapies

Vaccines & Immunization

Testing & Delivery Technologies

1 Market Overview
1.1 Novel Coronavirus (COVID-19) Vaccine Product Introduction
1.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size Forecast
1.3 Novel Coronavirus (COVID-19) Vaccine Market Trends & Drivers
1.3.1 Novel Coronavirus (COVID-19) Vaccine Industry Trends
1.3.2 Novel Coronavirus (COVID-19) Vaccine Market Drivers & Opportunity
1.3.3 Novel Coronavirus (COVID-19) Vaccine Market Challenges
1.3.4 Novel Coronavirus (COVID-19) Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Novel Coronavirus (COVID-19) Vaccine Players Revenue Ranking (2023)
2.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2019-2024)
2.3 Key Companies Novel Coronavirus (COVID-19) Vaccine Manufacturing Base Distribution and Headquarters
2.4 Key Companies Novel Coronavirus (COVID-19) Vaccine Product Offered
2.5 Key Companies Time to Begin Mass Production of Novel Coronavirus (COVID-19) Vaccine
2.6 Novel Coronavirus (COVID-19) Vaccine Market Competitive Analysis
2.6.1 Novel Coronavirus (COVID-19) Vaccine Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Novel Coronavirus (COVID-19) Vaccine Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 DNA
3.1.2 RNA
3.1.3 Others
3.2 Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Type
3.2.1 Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Novel Coronavirus (COVID-19) Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Novel Coronavirus (COVID-19) Vaccine Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Mild Symptom Patient
4.1.2 Critically Ill Patient
4.2 Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Application
4.2.1 Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Novel Coronavirus (COVID-19) Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Novel Coronavirus (COVID-19) Vaccine Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region
5.1.1 Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
5.2.2 North America Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
5.3.2 Europe Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
5.4.2 Asia Pacific Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
5.5.2 South America Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
5.6.2 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Novel Coronavirus (COVID-19) Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Novel Coronavirus (COVID-19) Vaccine Sales Value
6.3 United States
6.3.1 United States Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
6.3.2 United States Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Novel Coronavirus (COVID-19) Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
6.4.2 Europe Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Novel Coronavirus (COVID-19) Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
6.5.2 China Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Novel Coronavirus (COVID-19) Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
6.6.2 Japan Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Novel Coronavirus (COVID-19) Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
6.7.2 South Korea Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Novel Coronavirus (COVID-19) Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Novel Coronavirus (COVID-19) Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019-2030
6.9.2 India Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Novel Coronavirus (COVID-19) Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Inovio Pharmaceuticals
7.1.1 Inovio Pharmaceuticals Profile
7.1.2 Inovio Pharmaceuticals Main Business
7.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.1.4 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.1.5 Inovio Pharmaceuticals Recent Developments
7.2 Takis Biotech (Evvivax)
7.2.1 Takis Biotech (Evvivax) Profile
7.2.2 Takis Biotech (Evvivax) Main Business
7.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.2.4 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.2.5 Takis Biotech (Evvivax) Recent Developments
7.3 Zydus Cadila
7.3.1 Zydus Cadila Profile
7.3.2 Zydus Cadila Main Business
7.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.3.4 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.3.5 Codagenix, Inc. Recent Developments
7.4 Codagenix, Inc.
7.4.1 Codagenix, Inc. Profile
7.4.2 Codagenix, Inc. Main Business
7.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.4.4 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.4.5 Codagenix, Inc. Recent Developments
7.5 GeoVax, Inc.
7.5.1 GeoVax, Inc. Profile
7.5.2 GeoVax, Inc. Main Business
7.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.5.4 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.5.5 GeoVax, Inc. Recent Developments
7.6 Bravovax
7.6.1 Bravovax Profile
7.6.2 Bravovax Main Business
7.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.6.4 Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.6.5 Bravovax Recent Developments
7.7 Janssen Pharmaceutical Companies
7.7.1 Janssen Pharmaceutical Companies Profile
7.7.2 Janssen Pharmaceutical Companies Main Business
7.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.7.4 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.7.5 Janssen Pharmaceutical Companies Recent Developments
7.8 Altimmune
7.8.1 Altimmune Profile
7.8.2 Altimmune Main Business
7.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.8.4 Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.8.5 Altimmune Recent Developments
7.9 Vaxart
7.9.1 Vaxart Profile
7.9.2 Vaxart Main Business
7.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.9.4 Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.9.5 Vaxart Recent Developments
7.10 CanSino Biologics
7.10.1 CanSino Biologics Profile
7.10.2 CanSino Biologics Main Business
7.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.10.4 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.10.5 CanSino Biologics Recent Developments
7.11 ExpreS2ion Biotechnologies ApS
7.11.1 ExpreS2ion Biotechnologies ApS Profile
7.11.2 ExpreS2ion Biotechnologies ApS Main Business
7.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.11.4 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.11.5 ExpreS2ion Biotechnologies ApS Recent Developments
7.12 Clover Biopharmaceuticals
7.12.1 Clover Biopharmaceuticals Profile
7.12.2 Clover Biopharmaceuticals Main Business
7.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.12.4 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.12.5 Clover Biopharmaceuticals Recent Developments
7.13 GSK
7.13.1 GSK Profile
7.13.2 GSK Main Business
7.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.13.4 GSK Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.13.5 GSK Recent Developments
7.14 Vaxil Bio Ltd.
7.14.1 Vaxil Bio Ltd. Profile
7.14.2 Vaxil Bio Ltd. Main Business
7.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.14.4 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.14.5 Vaxil Bio Ltd. Recent Developments
7.15 Generex
7.15.1 Generex Profile
7.15.2 Generex Main Business
7.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.15.4 Generex Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.15.5 Generex Recent Developments
7.16 Novavax, Inc.
7.16.1 Novavax, Inc. Profile
7.16.2 Novavax, Inc. Main Business
7.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.16.4 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.16.5 Novavax, Inc. Recent Developments
7.17 Sanofi Pasteur
7.17.1 Sanofi Pasteur Profile
7.17.2 Sanofi Pasteur Main Business
7.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.17.4 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.17.5 Sanofi Pasteur Recent Developments
7.18 Baylor
7.18.1 Baylor Profile
7.18.2 Baylor Main Business
7.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.18.4 Baylor Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.18.5 Baylor Recent Developments
7.19 iBio, Inc.
7.19.1 iBio, Inc. Profile
7.19.2 iBio, Inc. Main Business
7.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.19.4 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.19.5 iBio, Inc. Recent Developments
7.20 Moderna, Inc.
7.20.1 Moderna, Inc. Profile
7.20.2 Moderna, Inc. Main Business
7.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.20.4 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.20.5 Moderna, Inc. Recent Developments
7.21 Curevac
7.21.1 Curevac Profile
7.21.2 Curevac Main Business
7.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.21.4 Curevac Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.21.5 Curevac Recent Developments
7.22 ImmunoPrecise
7.22.1 ImmunoPrecise Profile
7.22.2 ImmunoPrecise Main Business
7.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
7.22.4 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue (US$ Million) & (2019-2024)
7.22.5 ImmunoPrecise Recent Developments
8 Industry Chain Analysis
8.1 Novel Coronavirus (COVID-19) Vaccine Industrial Chain
8.2 Novel Coronavirus (COVID-19) Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Novel Coronavirus (COVID-19) Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Novel Coronavirus (COVID-19) Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart Inc.
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd
Generex
Novavax Inc
Sanofi Pasteur
Baylor
IBio Inc.
Moderna, Inc
CureVac
ImmunoPrecise
List of Tables
    Table 1. Novel Coronavirus (COVID-19) Vaccine Market Trends
    Table 2. Novel Coronavirus (COVID-19) Vaccine Market Drivers & Opportunity
    Table 3. Novel Coronavirus (COVID-19) Vaccine Market Challenges
    Table 4. Novel Coronavirus (COVID-19) Vaccine Market Restraints
    Table 5. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Novel Coronavirus (COVID-19) Vaccine Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Novel Coronavirus (COVID-19) Vaccine Product Type
    Table 9. Key Companies Time to Begin Mass Production of Novel Coronavirus (COVID-19) Vaccine
    Table 10. Global Novel Coronavirus (COVID-19) Vaccine Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Novel Coronavirus (COVID-19) Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Novel Coronavirus (COVID-19) Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Novel Coronavirus (COVID-19) Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Novel Coronavirus (COVID-19) Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region (2019-2024) & (%)
    Table 27. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Novel Coronavirus (COVID-19) Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Novel Coronavirus (COVID-19) Vaccine Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Novel Coronavirus (COVID-19) Vaccine Sales Value, (2025-2030) & (US$ Million)
    Table 31. Inovio Pharmaceuticals Basic Information List
    Table 32. Inovio Pharmaceuticals Description and Business Overview
    Table 33. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Inovio Pharmaceuticals (2019-2024)
    Table 35. Inovio Pharmaceuticals Recent Developments
    Table 36. Takis Biotech (Evvivax) Basic Information List
    Table 37. Takis Biotech (Evvivax) Description and Business Overview
    Table 38. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Takis Biotech (Evvivax) (2019-2024)
    Table 40. Takis Biotech (Evvivax) Recent Developments
    Table 41. Zydus Cadila Basic Information List
    Table 42. Zydus Cadila Description and Business Overview
    Table 43. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Zydus Cadila (2019-2024)
    Table 45. Zydus Cadila Recent Developments
    Table 46. Codagenix, Inc. Basic Information List
    Table 47. Codagenix, Inc. Description and Business Overview
    Table 48. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Codagenix, Inc. (2019-2024)
    Table 50. Codagenix, Inc. Recent Developments
    Table 51. GeoVax, Inc. Basic Information List
    Table 52. GeoVax, Inc. Description and Business Overview
    Table 53. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of GeoVax, Inc. (2019-2024)
    Table 55. GeoVax, Inc. Recent Developments
    Table 56. Bravovax Basic Information List
    Table 57. Bravovax Description and Business Overview
    Table 58. Bravovax Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Bravovax (2019-2024)
    Table 60. Bravovax Recent Developments
    Table 61. Janssen Pharmaceutical Companies Basic Information List
    Table 62. Janssen Pharmaceutical Companies Description and Business Overview
    Table 63. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Janssen Pharmaceutical Companies (2019-2024)
    Table 65. Janssen Pharmaceutical Companies Recent Developments
    Table 66. Altimmune Basic Information List
    Table 67. Altimmune Description and Business Overview
    Table 68. Altimmune Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Altimmune (2019-2024)
    Table 70. Altimmune Recent Developments
    Table 71. Vaxart Basic Information List
    Table 72. Vaxart Description and Business Overview
    Table 73. Vaxart Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Vaxart (2019-2024)
    Table 75. Vaxart Recent Developments
    Table 76. CanSino Biologics Basic Information List
    Table 77. CanSino Biologics Description and Business Overview
    Table 78. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of CanSino Biologics (2019-2024)
    Table 80. CanSino Biologics Recent Developments
    Table 81. ExpreS2ion Biotechnologies ApS Basic Information List
    Table 82. ExpreS2ion Biotechnologies ApS Description and Business Overview
    Table 83. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of ExpreS2ion Biotechnologies ApS (2019-2024)
    Table 85. ExpreS2ion Biotechnologies ApS Recent Developments
    Table 86. Clover Biopharmaceuticals Basic Information List
    Table 87. Clover Biopharmaceuticals Description and Business Overview
    Table 88. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Clover Biopharmaceuticals (2019-2024)
    Table 90. Clover Biopharmaceuticals Recent Developments
    Table 91. GSK Basic Information List
    Table 92. GSK Description and Business Overview
    Table 93. GSK Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of GSK (2019-2024)
    Table 95. GSK Recent Developments
    Table 96. Vaxil Bio Ltd. Basic Information List
    Table 97. Vaxil Bio Ltd. Description and Business Overview
    Table 98. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Vaxil Bio Ltd. (2019-2024)
    Table 100. Vaxil Bio Ltd. Recent Developments
    Table 101. Generex Basic Information List
    Table 102. Generex Description and Business Overview
    Table 103. Generex Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Generex (2019-2024)
    Table 105. Generex Recent Developments
    Table 106. Novavax, Inc. Basic Information List
    Table 107. Novavax, Inc. Description and Business Overview
    Table 108. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Novavax, Inc. (2019-2024)
    Table 110. Novavax, Inc. Recent Developments
    Table 111. Sanofi Pasteur Basic Information List
    Table 112. Sanofi Pasteur Description and Business Overview
    Table 113. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Sanofi Pasteur (2019-2024)
    Table 115. Sanofi Pasteur Recent Developments
    Table 116. Baylor Basic Information List
    Table 117. Baylor Description and Business Overview
    Table 118. Baylor Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Baylor (2019-2024)
    Table 120. Baylor Recent Developments
    Table 121. iBio, Inc. Basic Information List
    Table 122. iBio, Inc. Description and Business Overview
    Table 123. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 124. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of iBio, Inc. (2019-2024)
    Table 125. iBio, Inc. Recent Developments
    Table 126. Moderna, Inc. Basic Information List
    Table 127. Moderna, Inc. Description and Business Overview
    Table 128. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 129. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Moderna, Inc. (2019-2024)
    Table 130. Moderna, Inc. Recent Developments
    Table 131. Curevac Basic Information List
    Table 132. Curevac Description and Business Overview
    Table 133. Curevac Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 134. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of Curevac (2019-2024)
    Table 135. Curevac Recent Developments
    Table 136. ImmunoPrecise Basic Information List
    Table 137. ImmunoPrecise Description and Business Overview
    Table 138. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Products, Services and Solutions
    Table 139. Revenue (US$ Million) in Novel Coronavirus (COVID-19) Vaccine Business of ImmunoPrecise (2019-2024)
    Table 140. ImmunoPrecise Recent Developments
    Table 141. Key Raw Materials Lists
    Table 142. Raw Materials Key Suppliers Lists
    Table 143. Novel Coronavirus (COVID-19) Vaccine Downstream Customers
    Table 144. Novel Coronavirus (COVID-19) Vaccine Distributors List
    Table 145. Research Programs/Design for This Report
    Table 146. Key Data Information from Secondary Sources
    Table 147. Key Data Information from Primary Sources
    Table 148. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Novel Coronavirus (COVID-19) Vaccine Product Picture
    Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Novel Coronavirus (COVID-19) Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 4. Novel Coronavirus (COVID-19) Vaccine Report Years Considered
    Figure 5. Global Novel Coronavirus (COVID-19) Vaccine Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Novel Coronavirus (COVID-19) Vaccine Revenue in 2023
    Figure 7. Novel Coronavirus (COVID-19) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. DNA Picture
    Figure 9. RNA Picture
    Figure 10. Others Picture
    Figure 11. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 12. Global Novel Coronavirus (COVID-19) Vaccine Sales Value Market Share by Type, 2023 & 2030
    Figure 13. Product Picture of Mild Symptom Patient
    Figure 14. Product Picture of Critically Ill Patient
    Figure 15. Global Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Novel Coronavirus (COVID-19) Vaccine Sales Value Market Share by Application, 2023 & 2030
    Figure 17. North America Novel Coronavirus (COVID-19) Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 18. North America Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 19. Europe Novel Coronavirus (COVID-19) Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 20. Europe Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 21. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 22. Asia Pacific Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 23. South America Novel Coronavirus (COVID-19) Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 24. South America Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 25. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 26. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 27. Key Countries/Regions Novel Coronavirus (COVID-19) Vaccine Sales Value (%), (2019-2030)
    Figure 28. United States Novel Coronavirus (COVID-19) Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 29. United States Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 30. United States Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 31. Europe Novel Coronavirus (COVID-19) Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 32. Europe Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 33. Europe Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 34. China Novel Coronavirus (COVID-19) Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 35. China Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 36. China Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 37. Japan Novel Coronavirus (COVID-19) Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Japan Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 39. Japan Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 40. South Korea Novel Coronavirus (COVID-19) Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 41. South Korea Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 42. South Korea Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 43. Southeast Asia Novel Coronavirus (COVID-19) Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 45. Southeast Asia Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 46. India Novel Coronavirus (COVID-19) Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 47. India Novel Coronavirus (COVID-19) Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 48. India Novel Coronavirus (COVID-19) Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 49. Novel Coronavirus (COVID-19) Vaccine Industrial Chain
    Figure 50. Novel Coronavirus (COVID-19) Vaccine Manufacturing Cost Structure
    Figure 51. Channels of Distribution (Direct Sales, and Distribution)
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Novel Coronavirus Inactivated Vaccine Market Research Report 2025
Coronavirus Infection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Oral COVID 19 Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Covid 19 Vaccine Bottle Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Approved COVID 19 Vaccines Market Research Report 2025
COVID 19 DNA Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Coronavirus Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
COVID 19 Inactivated Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
COVID 19 Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Vials for COVID 19 Vaccine Market Research Report 2024
Covid 19 Vaccine Logistics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
COVID 19 Vaccine Transportation Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global COVID 19 Medicine Market Research Report 2024
Specific Antiviral Drugs for COVID 19 Market
Covid 19 Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Covid 19 Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
COVID 19 Vaccines Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Oral COVID 19 Antiviral Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
COVID 19 Vaccine Cold Chain Logistics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
COVID 19 Diagnostic Tests Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions